Unpacking the Safety Profile and Composition of ChondroFiller: What Patients Should Know
Introduction: Why Safety and Composition Matter
If you are exploring options for joint wear, you are probably asking: is ChondroFiller safe, and what is it actually made of? Understanding the material matters, because the type of substance injected into a joint affects both how your body responds and what risks are realistic. This article answers those questions with realistic expectations throughout.
What Is ChondroFiller and Who Could Benefit?
ChondroFiller is a CE-marked Class III medical device — a cell-free type I collagen scaffold manufactured by Meidrix Biomedicals in Germany and imported into the UK under prescription. When used as an outpatient injection, it is delivered under ultrasound guidance directly into the affected joint, without surgery, general anaesthetic, or hospital admission. It is suited to accessible lesions and smaller joints, or to patients who prefer to avoid surgery.
The collagen gel fills the worn or damaged area, adding a protective, cushioning layer. Because it recruits the patient's own progenitor cells from the surrounding tissue and subchondral bone, it acts as a regenerative scaffold rather than simply a cushion. Suitability is individual, and benefits vary; this is not a treatment that suits every patient or every defect size.
What Is Inside ChondroFiller?
ChondroFiller is a dual-component system supplied in a sterile, single-use, double-chamber syringe. The first chamber contains a solution of type I collagen — purified from the tail tendons of specific pathogen-free laboratory rats under strict quality controls. The second chamber contains a neutralising buffer solution. When the two components are mixed during application, the collagen self-gels at body temperature within approximately three to five minutes, forming an acellular scaffold that fills the contours of the defect.
There is no hyaluronic acid in the formulation. The cell-free nature of the device means it contains no living cells, which significantly lowers the risk of immune reactions. The final implant is a biocompatible hydrogel at a collagen concentration of 8 mg/ml, which gradually resorbs over one to two years as the body's own repair tissue matures and replaces it.
What Does the Research Say About Safety?
The published safety record for ChondroFiller is reassuring. Across more than 19,490 units sold since 2013, no serious device-related incidents have been reported. The overall complaint rate is around 0.06%, with the most common issue — non-gelation — occurring at a frequency of approximately 0.01%. Clinical studies consistently report a near-zero rate of significant adverse events.
A 2023 thumb-base osteoarthritis study reported improvements in pain and grip strength following ChondroFiller injection (Corain et al., 2023, Cartilage). In knee studies, patient-reported outcomes measured by the International Knee Documentation Committee (IKDC) score have improved by approximately 30 points over 12 to 36 months. Imaging using the MOCART score, which assesses repair tissue quality on MRI, has reached around 80 and above in knee and hip series.
Most published follow-up is in the short to medium term, and longer-term data continue to accumulate. The available evidence supports ChondroFiller as a generally safe and promising option, though outcomes cannot be guaranteed and the procedure remains unsuitable for some patients.
ChondroFiller Injection vs Liquid Cartilage: Two Distinct Pathways
It is worth clarifying a distinction that patients sometimes find confusing. ChondroFiller injection and Liquid Cartilage are not the same thing. The ChondroFiller injection is the non-surgical delivery pathway described throughout this article — an outpatient, ultrasound-guided procedure performed without a theatre or anaesthetic.
Liquid Cartilage is a separate, surgical protocol developed by Professor Paul Y. F. Lee. It delivers the ChondroFiller scaffold arthroscopically — through keyhole surgery under anaesthetic — combined with biological adjuncts such as platelet-rich fibrin or platelet-rich plasma, and where indicated the patient's own mesenchymal stem cells from bone-marrow concentrate or micro-fragmented fat. This approach is used for larger or load-bearing defects in joints such as the knee, hip, shoulder, or ankle where the injection route alone may not be sufficient. The CE marking and device evidence discussed in this article belong to ChondroFiller (the scaffold material itself), regardless of which delivery pathway is used.
Choosing between the injection pathway and the surgical Liquid Cartilage protocol depends on the size and location of the defect, the joint involved, and the patient's overall clinical picture. A specialist assessment is needed to determine which approach — if either — is appropriate.
What Should Patients Keep in Mind?
If you are considering ChondroFiller injection, several points are worth discussing with your specialist. Your medical history, any allergies, and other health conditions can all affect suitability. Careful diagnosis and personalised planning are essential. The injection is not a cure, and benefits vary; realistic expectations are central to a good outcome. Any treatment decision should be based on a thorough individual assessment.
Conclusion
ChondroFiller is a biocompatible, cell-free collagen scaffold with a strong published safety record. When delivered as an outpatient injection, it offers a non-surgical option for patients with joint wear or localised cartilage defects who are suitable candidates. It is not a cure and does not reverse arthritis. For advice tailored to your situation — and to understand whether the injection route or the surgical Liquid Cartilage protocol is more appropriate — a consultation with a specialist in cartilage and joint preservation is the right starting point. The London Cartilage Clinic on Harley Street provides that kind of individual assessment.
References
Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.
Weizel, A., Distler, T., Schneidereit, D., & Friedrich, O. (2020). Complex mechanical behavior of human articular cartilage and hydrogels for cartilage repair. Acta Biomaterialia. [Note: this is a biomechanical characterisation study of the hydrogel material, not a clinical outcomes paper.]
Frequently Asked Questions
- ChondroFiller is a CE-marked, cell-free type I collagen scaffold — not a painkiller, steroid, or hyaluronic acid filler. It self-gels inside the joint and acts as a regenerative matrix, recruiting the body's own progenitor cells to support repair. It is delivered under ultrasound guidance as an outpatient injection, without surgery or general anaesthetic.
- Published experience across more than 19,490 units sold since 2013 shows no serious device-related incidents and an overall complaint rate of around 0.06%. Clinical studies consistently report a near-zero rate of significant adverse events. Careful patient selection and thorough pre-treatment assessment are central to keeping the procedure safe; benefits still vary between individuals.
- People with osteoarthritis or localised cartilage wear who prefer a non-surgical option, and whose defect size and joint location are suitable for the injection route. Suitability is determined individually after clinical assessment; the injection is not appropriate for every patient or every defect.
- ChondroFiller injection is a non-surgical, ultrasound-guided outpatient procedure — no theatre, no anaesthetic. Liquid Cartilage is Professor Lee's keyhole surgical protocol, which delivers the ChondroFiller scaffold arthroscopically alongside biological adjuncts (platelet-rich fibrin, PRP, and sometimes the patient's own mesenchymal stem cells). Liquid Cartilage is reserved for larger or load-bearing defects where the injection alone is unlikely to be sufficient. The CE marking and device safety data discussed in this article relate to ChondroFiller (the scaffold material) regardless of which pathway is used.
- Key questions include whether the defect size and location make you a suitable candidate for the injection route (versus the surgical Liquid Cartilage option), what realistic outcomes look like in your case, how many sessions may be needed, what the recovery involves, and what happens if response is limited. A thorough discussion of your medical history and expectations before proceeding is essential.
Where to go from here
A few next steps tailored to what you have just read.
Legal & Medical Disclaimer
This article is written by an independent contributor and reflects their own views and experience, not necessarily those of London Cartilage Clinic. It is provided for general information and education only and does not constitute medical advice, diagnosis, or treatment.
Always seek personalised advice from a qualified healthcare professional before making decisions about your health. London Cartilage Clinic accepts no responsibility for errors, omissions, third-party content, or any loss, damage, or injury arising from reliance on this material.
If you believe this article contains inaccurate or infringing content, please contact us at [email protected].
